Tendances de la Recherche Médicale

Les publications les plus percutantes de la semaine dans 29 spécialités, sélectionnées par IA

Dernière mise à jour: 22 mai 2026

Gastro-entérologie5 articles

Impact 2

Amplification of pro-proliferative genes adjacent to the F3 gene in pancreatic adenocarcinoma is associated with worse outcomes.

Publié: 2026-12-01

Cell cycle (Georgetown, Tex.)

MediLens Indexé: 2026-05-23

This study explores the relationship between gene amplification of ARHGAP29 and SLC44A3 and the elevated expression of the F3 gene in pancreatic adenocarcinoma (PAAD). Using CNV analyses from CPTAC-PAAD and TCGA-PAAD data sets, it was found that patients with higher CNs for these genes had signif...

Lire sur PubMed
Impact 2

Publié: 2026-12-01

Journal of enzyme inhibition and medicinal chemistry

MediLens Indexé: 2026-05-22

This study investigates the p53-Y220C mutation, which is associated with increased aggressivity in gastric cancer and offers a target for small molecule therapies. The mutation causes misfolding of p53 due to thermal instability and creates a pocket for small molecules, along with an additional f...

Lire sur PubMed
Impact 3

Reprogramming of the hepatic ubiquitin‑immune axis: A unifying mechanism in liver disease progression (Review).

Publié: 2026-07-01

Molecular medicine reports

MediLens Indexé: 2026-05-23

This review proposes a new paradigm for the progression of liver disease, suggesting it arises from systematic reprogramming of the ubiquitin code in the hepatic microenvironment. Key E3 ligases and deubiquitinases shift from protective roles to drivers of disease progression, affecting various c...

Lire sur PubMed
Impact 3

ZBTB16 upregulation maintains copper homeostasis to support esophageal tumor progression.

Publié: 2026-07-01

Molecular medicine reports

MediLens Indexé: 2026-05-23

This study investigates the role of ZBTB16 in esophageal cancer, revealing that it is highly expressed in cancer tissues and cell lines. Knockdown of ZBTB16 inhibited cancer cell proliferation and migration, increased cell death, and affected mitochondrial function. In vivo, ZBTB16 knockdown supp...

Lire sur PubMed
Impact 2

Integrin beta 4 promotes colorectal cancer progression by upregulating Ezrin and activating the Wnt/β‑catenin signaling pathway.

Publié: 2026-07-01

International journal of oncology

MediLens Indexé: 2026-05-23

The study investigates the role of Integrin beta 4 (ITGB4) in colorectal cancer (CRC) progression, aiming to clarify its oncogenic mechanism and identify downstream molecular effectors for potential targeted therapy.

Lire sur PubMed

Recevez des résumés quotidiens personnalisés

Des médecins du monde entier commencent leur journée avec des revues de littérature par IA, livrées à 7h.

Essai gratuit de 14 jours